Lexicon Pharmaceuticals, Inc. (LXRX)
Evaluation: Based on all recent filings, financial statements, and news.
See full evaluationAsk a question about Lexicon Pharmaceuticals, Inc. (LXRX)
Go deeper and ask any question about LXRX
Company Performance
Current Price
as of Sep 13, 2024$1.70
P/E Ratio
N/A
Market Cap
$614.54M
Description
Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its drug candidates include: LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain, and Sotagliflozin, a treatment for heart failure and type 1 diabetes. The company was founded by Brian P. Zambrowicz and Arthur T. Sands on July 7, 1995 and is headquartered in The Woodlands, TX.
Metrics
Overview
- HQThe Woodlands, TX
- SectorHealth Technology
- IndustryPharmaceuticals: Major
- TickerLXRX
- Price$1.7+1.80%
Trading Information
- Market Cap$614.54M
- Float96.55%
- Average Daily Volume (1m)2,456,798
- Average Daily Volume (3m)2,886,911
- EPS-$0.77
Company
- Revenue$3.64M
- Rev Growth (1yr)419.56%
- Net Income-$53.43M
- Gross Margin81.48%
- EBITDA Margin-3,352.46%
- EBITDA-$55.22M
- EV$317.92M
- EV/Revenue87.32
- P/EN/A
- P/S145.13
Documents
SEC Filings
Earnings Calls
Factset Street Account
Wikipedia